Tristearate

Tristearate (Glyceryl Tristearate / Tristearin): A Comprehensive Reference

1. Identity and Chemical Nomenclature

Stearin, or tristearin, or glyceryl tristearate is a triglyceride derived from three units of stearic acid. Also known as tristearin or glyceryl tris(octadecanoate), it is a saturated triglyceride formed from the esterification of glycerol with stearic acid. The term "tristearate" as used in the supplement and food industry most commonly refers to this same compound, glyceryl tristearate, in which the glycerol backbone is fully esterified at all three positions.

Stearin, also known as tristearin or glyceryl tristearate, is a triglyceride composed of one glycerol molecule esterified with three molecules of stearic acid, having the molecular formula C₅₇H₁₁₀O₆. With the CAS number 555-43-1, this white to off-white crystalline solid has a melting point around 65°C and is sparingly soluble in water but soluble in organic solvents and fats.

The compound is known under numerous synonyms in the technical and regulatory literature. These include: 1,2,3-Propanetriol trioctadecanoate; Dynasan 118; Glycerol tristearate; Glycerol, trioctadecanoate; Glyceryl tristearate; Glycowax S 932; Hardened oil; Octadecanoic acid, 1,2,3-propanetriyl ester; Spezialfett 118; Stearic acid triglyceride; Stearic acid triglycerin ester; Stearic triglyceride; Stearin; Stearin, tri-; Stearoyl triglyceride; Trioctadecanoin.

The ChEBI definition characterizes tristearoylglycerol as a triglyceride that is glycerol in which all three hydroxy groups have been formally esterified with stearic acid. It has a role as a plant metabolite and a Caenorhabditis elegans metabolite, and derives from octadecanoic acid.

Physical Properties

Glycerol tristearate is a white, microfine crystalline powder. It is soluble in hot alcohol, benzene and chloroform, very slightly soluble in cold alcohol, in ether and in petroleum ether, and insoluble in water. Because of its hydrophobic nature, it does not dissolve in water but is soluble in organic solvents such as chloroform, ether, and hot ethanol. Because of its stability and solid consistency, it contributes to the hardness of fats in natural oils and butters, and plays a role in giving products like cocoa butter and shea butter their solid form at room temperature.

2. Natural Sources and Botanical/Animal Origin

Chemically, glyceryl tristearate belongs to the class of mono-, di-, and triglycerides, which are naturally occurring compounds found in vegetable oils and animal fats. Tristearin occurs naturally in animal fats such as beef tallow, lard, and dairy fats, as well as in certain plant oils like cocoa butter and shea butter, which are known for their high content of saturated fatty acids.

Glyceryl tristearate is obtained from animal fats created as a byproduct of processing beef. It can also be found in tropical plants such as palm. Stearin is also a side product obtained during the extraction of cod liver oil, removed during the chilling process at temperatures below −5°C.

Glyceryl tristearate is a natural product found in Lysiphlebia japonica, Aphis forbesi, and other organisms. Biologically, glycerol tristearate is a common constituent of animal and vegetable fats and serves as an energy storage molecule. In living organisms, triglycerides like stearin are metabolized to release fatty acids and glycerol, which are further processed to generate energy. Additionally, it has been identified as a plant metabolite, indicating its natural occurrence in certain plant tissues.

Industrial and Commercial Sourcing

Glycerol tristearate is a triglyceride derived from the esterification of glycerol with stearic acid, a saturated fatty acid. It is typically sourced from natural fats and oils through a process involving the hydrogenation of vegetable oils, which facilitates its pure and controlled production. It can also be prepared by reacting glycerin with stearic acid in the presence of a suitable catalyst such as aluminum oxide. Glyceryl tristearate can also be obtained by interesterification, exploiting its higher melting point which allows the higher-melting tristearin to be removed from the equilibrated mixture.

Tristearin is the main component of fully-hydrogenated soybean and rapeseed oil. The solid fraction rich in saturated triglycerides such as tristearin is primarily isolated from natural animal fats and vegetable oils through industrial processes that exploit differences in melting points.

3. Common Forms and Preparations

Tristearate appears in several distinct forms and preparations across food, pharmaceutical, nutraceutical, and cosmetic applications:

• Bulk powder / crystalline solid: Glycerol tristearate is a white, microfine crystalline powder used as a raw material in downstream formulations.
• Food-grade additive: Glyceryl tristearate is a formulation aid, lubricant, and release agent, prepared by reacting stearic acid with glycerol in the presence of a suitable catalyst. The additive is used as a crystallization accelerator in cocoa products; a formulation aid in confections; a formulation aid in fats and oils; and a winterization and fractionation aid in fat and oil processing.
• Pharmaceutical excipient (solid lipid nanoparticles): It is used in controlled-release systems, and as a matrix-forming agent in solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs).
• Cosmetic/topical preparations: Tristearin is also used to form the lipid matrices of solid lipid nanoparticles. Formulations containing tristearin are used in cosmetic products to condition skin and as thickening agents.
• Textile and industrial uses: It is used in textile sizes, candles, soaps, adhesive pastes, and metal polishes, and also for waterproofing paper, for leather stuffing, and as a lubricant in cosmetics.

4. Traditional and Historical Use

Tristearate as an isolated chemical entity is a product of modern analytical and industrial chemistry; it was not historically identified or used as a discrete compound. However, the fats and oils in which it naturally predominates—tallow, lard, cocoa butter, and shea butter—have extensive histories of use across many cultures and time periods.

While not frequently singled out as an herbal remedy, tristearate has played a supportive role in traditional medicine and pharmaceutical preparations. Its gentle nature made it suitable for sensitive skin, and it was often included in topical applications for soothing dryness, minor wounds, and irritations.

Tallow and animal stearin were used historically in candle-making, soap production, and as a base for medicinal ointments across European and Near Eastern traditions. Glycerol tristearate was formerly used in making candles. Cocoa butter, one of the richest natural sources of the compound, has been used in Mesoamerican food preparation for millennia, and was adopted in European confectionery and pharmacy from the sixteenth century onward. Shea butter, another significant natural source, has a long history of topical use in West Africa for skin conditioning and wound care.

Tristearate has also been used in combination with herbs and other botanicals, enhancing the overall effectiveness of herbal formulations. By acting as a carrier or binding agent, it allowed for the even distribution of herbal extracts, ensuring consistent dosing in capsules and tablets.

In more modern times, tristearate continues to be a valued excipient in nutraceuticals and dietary supplements, contributing to product stability, palatability, and ease of use.

5. Key Constituents and Active Compounds

Tristearate is itself a single chemical compound, not a botanical extract with multiple phytochemical constituents. Its biological activity is therefore understood primarily through its constituent moieties and their downstream metabolic fate.

Stearic Acid (Octadecanoic Acid, C18:0)

Upon digestion, tristearate is hydrolyzed to yield three molecules of stearic acid and one molecule of glycerol. Stearic acid shares many physical properties with the other long-chain saturated fatty acids (SFAs) but has different physiological effects. Delta-9 desaturase (Δ9) catalyzes the conversion of saturated fatty acids, such as palmitic acid and stearic acid, into their monounsaturated forms, palmitoleic and oleic acid, respectively.

Stearoyl-CoA desaturase (SCD; EC 1.14.19.1) is an iron-containing enzyme that catalyzes a rate-limiting step in the synthesis of unsaturated fatty acids. The principal product of SCD is oleic acid, which is formed by desaturation of stearic acid. A series of redox reactions, during which two electrons flow from NADH to flavoprotein cytochrome b5, then to the electron acceptor cytochrome b5 as well as molecular oxygen, introduces a single double bond within a row of methylene fatty acyl-CoA substrates. The complexed enzyme adds a single double bond between C9 and C10 of long-chain acyl-CoAs.

The ratio of stearic acid to oleic acid has been implicated in the regulation of cell growth and differentiation through effects on cell membrane fluidity and signal transduction.

Glycerol

The glycerol backbone released during hydrolysis of tristearate enters normal carbohydrate metabolism. It can be phosphorylated to glycerol-3-phosphate and incorporated into gluconeogenesis or lipid synthesis pathways. This is a well-established route of fat catabolism, common to all dietary triglycerides.

Structural Role as a Triglyceride

In living organisms, tristearate acts as a major energy reserve, being stored in adipose tissues where it can be broken down into glycerol and free fatty acids during times of energy demand. Delta-9 desaturase (Δ9) activity is important for most lipid functions, such as membrane fluidity, lipoprotein metabolism, and energy storage.

6. Mechanisms of Action

Lipase-Mediated Hydrolysis and Fat Digestion

The apparent digestibility of stearic acid is associated with stearoyl density within the triacylglycerol molecule. Soap formation appears not to be a major factor in the reduced digestion of stearic acid from tristearin under regular dietary circumstances, but both microcrystallinity and reduced digestibility of tri-, di- and monostearoylglycerols appears to be important.

The addition of triolein increased the absorption of labeled tristearin in control rats but not in bile fistula rats, suggesting that poor solubility in bile salt solution is an important step hindering the absorption of tristearin, and that triolein stimulates absorption by increasing this solubility.

Solubilization of high-melting-point tristearin in low-melting-point oils improves the digestibility of its stearic acid, particularly when emulsified or liquidized at above melting point.

Desaturation of Absorbed Stearic Acid

Results indicate that absorption of palmitic acid and stearic acid was similar when all components of the mixture used to formulate the deuterated fat mixture were kept above the melting point of tristearin. The percent of stearic acid (18:0) desaturated to 9c-18:1 (oleic acid) was higher than the percent of palmitic acid desaturated to 9c-16:1 (9.2% vs. 3.9%).

Potential Effect on Cholesterol Micelle Formation

Poorly digested tristearin may disturb micelle formation in the gut, resulting in an altered bile acid profile and reduced cholesterol absorption, which, in turn, lowers plasma cholesterol. This mechanism, however, has been characterized primarily in animal models and its relevance to normal human dietary consumption remains uncertain.

7. Scientific Evidence by Area of Use

7.1 Digestibility and Caloric Availability

Evidence type: Human digestibility data and mechanistic analyses.

The efficiency with which human subjects digest stearoyl from cocoa butter still remains uncertain, while the digestion of total long-chain fat from this source is 0.89–0.95 g/g, high in comparison with 0.33 g/g for Salatrim 23CA and 0.15 g/g for tristearin in their prepared states. This observation is significant: pure tristearin in its crystalline, unemulsified form is substantially less digestible in humans than other common dietary fats.

The digestibility of tristearin was only 20% that of corn oil, and excretion of fecal lipids was several times normal, i.e., 1000 mg/d versus 100–225 mg/d for trimyristin, LLL, or partially hydrogenated soybean oil. This finding was made in a rat study and directly demonstrates the markedly reduced caloric extraction from pure tristearin compared with more common dietary fats.

Dietary intakes of stearoyl of 0.05–0.65 g stearic acid equivalent/kg body weight (cf typical intake of 0.2 g stearic acid equivalent/kg body weight in the Western diet) indicate that the 'true' digestibility of stearoyl is 0.98 (SE 0.01) g/g, with apparent digestibility less than this value at low intakes owing to endogenous stearic acid excretion. This suggests that stearic acid, when well-mixed and emulsified as it occurs in normal foods, is almost completely digested, while pure crystalline tristearin is a special case with markedly reduced digestibility.

Evidence strength: Moderate (human and animal data), with important qualifications based on physical form and food matrix.

7.2 Cardiovascular Risk and Plasma Lipid Effects

Evidence type: Systematic review of epidemiological and clinical studies; the evidence relates specifically to stearic acid (the primary metabolite of tristearate) rather than tristearate itself as a supplement.

High stearic acid (STA) soybean oil is a trans-free, oxidatively stable, non-LDL-cholesterol-raising oil. Epidemiologic and clinical studies evaluated the relation between STA and cardiovascular disease (CVD) risk factors, including plasma lipids and lipoproteins, hemostatic variables, and inflammatory markers. In comparison with other saturated fatty acids, STA lowered LDL cholesterol, was neutral with respect to HDL cholesterol, and directionally lowered the ratio of total to HDL cholesterol.

STA tended to raise LDL cholesterol, lower HDL cholesterol, and increase the ratio of total to HDL cholesterol in comparison with unsaturated fatty acids.

An unfavorable effect on fibrinogen concentrations did not occur until the amount of dietary STA exceeded 9% of energy. Although the preponderance of evidence indicates that dietary STA has a neutral effect on plasma lipids, lipoproteins, and hemostatic factors, it may be helpful to undertake a longer-term feeding study at the newly established 90th percentile of intake to confirm expected effects on these measures.

Studies involving between 30 and 80 subjects who consumed diets high in either trans fatty acids (TFA) or STA for 21 to 35 days were conducted, with subjects then switching to the other diet for an equivalent period of time. These crossover designs were of modest size and short duration.

Meta-analyses of observational studies found no association between SFA intake and heart disease, while meta-analyses of randomized controlled trials were inconsistent but tended to show a lack of an association.

Evidence strength: Moderate for stearic acid specifically; stearic acid appears metabolically distinct from other saturated fatty acids in its lipid effects. Direct clinical evidence for tristearate as such (rather than as a source of stearic acid) is absent.

7.3 As a Pharmaceutical Drug Delivery Excipient (Solid Lipid Nanoparticles)

Evidence type: Preclinical (in vitro and animal), with limited human data on outcomes.

Solid lipid nanoparticles (SLNs) are prepared from lipids which are solid at room temperature as well as at body temperature. Different solid lipids are exploited to produce SLNs, including tristearin (Dynasan® 118).

Researchers developed Tween 80-emulsified and TPGS 1000-emulsified tristearin-based lipidic nanoparticles, and by comparing both formulations concluded that the intestinal absorption and relative oral bioavailability of docetaxel in rats were further improved in TPGS 1000-emulsified SLNs as compared to Tween 80-emulsified SLNs, probably due to better inhibition of drug efflux by TPGS 1000, along with intestinal lymphatic uptake.

Drug-loaded solid lipid nanoparticles have been self-assembled from spray-dried microparticles comprising poly(vinylpyrrolidone) (PVP) loaded with glyceryl tristearate (GTS) and either indomethacin or 5-fluorouracil. The SLNs provide a non-toxic delivery platform for both hydrophobic and hydrophilic drugs. They show extended release profiles over more than 24 hours, and in permeation studies the drug cargo is seen to accumulate inside cancer cells.

Different SLNs were prepared using tristearin, glycerol monostearate, stearic acid, and Compritol® 888 ATO by solvent diffusion method. SLNs prepared with Compritol® 888 ATO demonstrated better drug-loading and release characteristics than other formulations in that specific study.

Evidence strength: Preclinical only; the role of tristearate here is as a biocompatible excipient rather than as a bioactive ingredient per se. No direct human clinical trials have evaluated health outcomes from oral supplementation of tristearate itself in an SLN context.

7.4 Skin Conditioning and Topical Applications

Evidence type: Formulation science and cosmetic chemistry; no controlled clinical trials specifically on tristearate as a standalone topical ingredient.

One of the primary reasons for incorporating glycerol tristearate into cosmetic products is its ability to act as an emollient. This means it helps to soften and smooth the skin, providing a luxurious feel and improving the overall user experience. Beyond its emollient qualities, it also serves as a thickening agent.

Evidence strength: Weak to absent for clinical outcomes. Its use as a skin emollient is based on its lipid properties and its structural similarity to other well-characterized fat-based emollients.

7.5 Energy Metabolism and Adipose Tissue Storage

In living organisms, tristearin acts as a major energy reserve, being stored in adipose tissues where it can be broken down into glycerol and free fatty acids during times of energy demand. This is a general property of dietary triglycerides, not specific to tristearate as a supplemental agent. No human clinical studies specifically address tristearate supplementation for effects on body composition or energy metabolism.

Evidence strength: Established biochemical fact; no clinical supplementation studies.

8. Body Systems and Health Areas of Association

• Gastrointestinal / Digestive System: The apparent digestibility of stearic acid is associated with stearoyl density within the triacylglycerol molecule. Intestinal hydrolysis by pancreatic lipase is a central step. Tristearate's physical state (crystallinity, melting point) critically determines its digestive fate in humans.
• Cardiovascular System: As a precursor of stearic acid, which is subject to desaturation to oleic acid in vivo, tristearate may be associated with relatively neutral cardiovascular lipid effects compared to other saturated fatty acid-rich fats. In comparison with other saturated fatty acids, stearic acid lowered LDL cholesterol, was neutral with respect to HDL cholesterol, and directionally lowered the ratio of total to HDL cholesterol.
• Lipid Metabolism / Hepatic System: Delta-9 desaturase catalyzes the conversion of stearic acid into oleic acid. Delta-9 desaturase activity is important for most lipid functions, such as membrane fluidity, lipoprotein metabolism, and energy storage.
• Skin / Integumentary System: As an emollient and occlusive agent in topical preparations, tristearate is associated with skin barrier function and moisturization.
• Drug Delivery Platforms: Glyceryl tristearate is a key lipid matrix material for the formulation of solid lipid nanoparticles (SLNs), which are advanced drug delivery systems. In this role it is linked to bioavailability enhancement across multiple organ systems depending on the encapsulated drug.

9. Dosage Forms and Reported Dosages

Tristearate does not have an established human supplemental dosage. The following information reflects dosages or concentrations reported in studies and formulation research:

• Animal digestibility studies: In sheep studies, diets contained 7.5% added tristearin for 21 days.
• Human digestibility reference intakes: Dietary intakes of stearoyl of 0.05–0.65 g stearic acid equivalent/kg body weight were evaluated, with a typical intake of 0.2 g stearic acid equivalent/kg body weight in the Western diet.
• Clinical CVD studies (stearic acid as metabolite of tristearate): Studies involved between 30 and 80 subjects who consumed diets high in stearic acid or trans fatty acids for 21 to 35 days. Specific amounts of stearic acid in the diet were varied as a proportion of total energy in those controlled feeding trials.
• Food additive use: Glyceryl tristearate is used as a formulation aid, lubricant, and release agent in food manufacturing at concentrations determined by Good Manufacturing Practices (GMP), not fixed regulatory limits per serving.
• Pharmaceutical nanoparticle formulations: The concentration of tristearin in SLN research formulations varies widely by study design and target drug. No standard supplemental human dose exists.

No clinically established supplemental dose of tristearate has been defined by any pharmacopeial or regulatory body. Clinical trials specifically evaluating the health benefits or physiological effects of tristearate in humans are limited, with available research supporting its inertness and utility as a processing aid rather than as a bioactive nutritional component.

10. Regulatory Status

Glyceryl tristearate, a component of glyceryl palmitostearate, is approved as a multipurpose food additive in 21 CFR 172.811 under U.S. FDA regulations. Mono- and diglycerides prepared from fats, oils, or fat-forming acids derived from edible sources, including palmitic and stearic acids, are affirmed as GRAS in 21 CFR 184.1505. Stearic and palmitic acid are approved as multipurpose food additives in 21 CFR 172.860.

Glyceryl tristearate has not been formally approved as Generally Recognized as Safe (GRAS) by the FDA under its current regulatory classification. However, the absence of GRAS status does not indicate safety concerns; rather, it reflects the regulatory pathway taken or the lack of a formal petition.

11. Safety Considerations and Known Interactions

General Metabolic Safety

FDA adverse event data shows zero reported incidents associated with glyceryl tristearate, and no product recalls have been linked to this ingredient. The compound is closely related to food-grade stearic acid and glycerol, both widely recognized as safe substances with extensive use history in the food industry.

Studies on stearic acid and its derivatives show they are readily metabolized with no evidence of bioaccumulation. Research on food-grade glycerol esters demonstrates safety profiles consistent with their GRAS status. The structural similarity to naturally occurring triglycerides suggests a favorable safety profile.

Reduced Digestibility and Fecal Fat Excretion

A notable and source-substantiated safety consideration is the markedly reduced digestibility of pure, crystalline tristearate. The digestibility of tristearin was only 20% that of corn oil, and excretion of fecal lipids was several times normal. At high supplemental doses of pure, unemulsified tristearate, this could result in significant steatorrhea (excess fat in the stool). This risk is substantially mitigated when tristearate is well-dispersed in other food fats or in an emulsified state, as solubilization of high-melting-point tristearin in low-melting-point oils improves the digestibility of its stearic acid, particularly when emulsified or liquidized at above melting point.

Cholesterol and Lipid Interactions

Stearic acid tended to raise LDL cholesterol, lower HDL cholesterol, and increase the ratio of total to HDL cholesterol in comparison with unsaturated fatty acids. While stearic acid is considered more favorable than other saturated fats with respect to LDL cholesterol, it is not entirely neutral when compared to monounsaturated or polyunsaturated fats. Large amounts of dietary saturated fat from any source, including stearic acid-rich fats, may still contribute to less favorable lipid profiles when substituted for unsaturated fats.

Cholesterol Absorption Modulation

Poorly digested tristearin may disturb micelle formation in the gut, resulting in an altered bile acid profile and reduced cholesterol absorption, which, in turn, lowers plasma cholesterol. This effect, derived from animal model data, suggests a potential interaction with fat-soluble nutrient and drug absorption, particularly at high intake levels of pure tristearin.

Interactions with Pharmaceutical Drugs in SLN Formulations

In the context of solid lipid nanoparticle formulations, tristearin-based lipidic nanoparticles may improve the intestinal absorption and relative oral bioavailability of encapsulated drugs such as docetaxel, due to intestinal lymphatic uptake and inhibition of drug efflux. This pharmacokinetic interaction is relevant to the pharmaceutical use of tristearate as an excipient, not to dietary supplementation per se, but indicates that co-administration of high-fat, tristearate-containing foods with certain lipophilic drugs could theoretically alter drug absorption.

Animal-Model Cholesterol Data

Tristearin increases serum cholesterol levels in rats. This animal study finding should be interpreted cautiously; the differential digestibility of tristearin between species and across dietary fat matrices means that rodent data may not directly translate to human physiology.

No Known Specific Drug Interactions in Humans

Clinical trials specifically evaluating the health benefits or physiological effects of tristearate in humans are limited, with available research supporting its inertness and utility as a processing aid rather than as a bioactive nutritional component. No well-characterized, source-documented drug-drug or drug-supplement interactions have been established for dietary tristearate at supplement-relevant doses in controlled human studies.

12. Evidence Gaps and Research Status

The scientific literature as of the available evidence base contains no randomized controlled trials in which glyceryl tristearate itself—distinct from stearic acid or other related lipids—was administered to human subjects as a dietary supplement for the purpose of achieving a defined health outcome. The compound's scientific study has focused predominantly on: (1) its digestibility and physical chemistry as a dietary fat; (2) the cardiovascular effects of its metabolic product, stearic acid; and (3) its utility as an excipient in pharmaceutical and nutraceutical delivery systems. Because stearic acid shares many physical properties with the other long-chain SFAs but has different physiological effects, it is being evaluated as a substitute for trans fatty acids in food manufacturing. For stearic acid to become the primary replacement for TFA, it is essential that its physical properties and biological effects be well understood.

Research is needed to evaluate the effects of stearic acid on emerging CVD risk markers such as fibrinogen and to understand the responses in different populations. This research gap applies equally to tristearate as a stearic acid source.

References

• Mensink RP et al. "The absorption of stearic acid from triacylglycerols: an inquiry and analysis." Nutrition Research Reviews (2009). PubMed PMID: 19087439
• Nutrition Research Reviews – "The absorption of stearic acid from triacylglycerols: an inquiry and analysis." Cambridge University Press
• Hunter JE, Zhang J, Kris-Etherton PM. "Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review." Am J Clin Nutr. 2010;91(1):46-63. PubMed PMID: 19939984
• American Journal of Clinical Nutrition – "Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review." Full text
• Kris-Etherton PM et al. "Dietary stearic acid and risk of cardiovascular disease: intake, sources, digestion, and absorption." PubMed PMID: 16477802
• Journal of Clinical Lipidology – "Saturated fats and cardiovascular health: Current evidence and controversies." 2021
• Astrup A et al. "Dietary saturated fat and heart disease: a narrative review." Atherosclerosis. 2020. PubMed PMID: 31841151
• PMC – "Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery." PMC3066374
• PMC – "A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery." PMC9012924
• International Journal of Pharmaceutics – "Solid lipid nanoparticles self-assembled from spray dried microparticles." ScienceDirect
• Emken EA et al. "Influence of linoleic acid on desaturation and uptake of deuterium-labeled palmitic and stearic acids in humans." PubMed PMID: 8399342
• Wikipedia – "Stearoyl-CoA 9-desaturase"
• PMC – "Delta-9 desaturase reduction in gastrointestinal cells induced to senescence by doxorubicin." PMC11891767
• Journal of Nutrition – "Glyceride Stearic Acid Content and Structure Affect the Energy Available to Growing Rats." 2002
• Journal of Dairy Science – "Digestion and Absorption of Lipids and Bile Acids in Sheep Fed Stearic Acid, Oleic Acid, or Tristearin." ScienceDirect
• NCATS Inxight Drugs — GLYCERYL TRISTEARATE
• Federal Register, Vol. 60, Issue 238 (December 12, 1995) – FDA ruling on glyceryl palmitostearate, referencing 21 CFR 172.811 approval of glyceryl tristearate
• AdditiveFacts.com – "Is Glyceryl Tristearate Safe? Side Effects & 2026 FDA & EFSA Verdict"
• Ataman Chemicals – Glyceryl Tristearate Product Description
• Grokipedia – "Stearin"